FAS and neoplasm: Indeed, downregulation of FasL expression was recently shown to result in an increased anti-tumor immune challenge and decreased tumor formation in vivo, providing functional evidence in favor of the 'Fas counterattack' as a mechanism of tumour immune evasion [20].